Key Highlights
- Marsh (NYSE:MRSH) agreed on November 10, 2026 to acquire Wilshire, an Investment advisory and index firm with about USD 221 billion of Assets under management and USD 1.6 trillion of assets under advisement, from CC Capital and Motive Partners.
- Financial terms were not disclosed, and the deal is expected to close in the first quarter of 2027, subject to regulatory approvals and client consents.
- Separately, cell therapy tools maker MaxCyte agreed to acquire Akron Bio from affiliates of Arcline for total consideration of USD 151.8 million, a deal expected to nearly double its Revenue base.
- The MaxCyte price comprises USD 105.0 million in cash, about USD 26.8 million in stock and USD 20.0 million of guaranteed deferred payments, with closing expected before the end of 2026.
Marsh Adds Wealth and Retirement Scale
Marsh, the insurance broking and professional services group, is buying Wilshire to expand its investments business. Wilshire advises institutional investors such as public and private retirement plans, endowments and foundations, and it has a growing advisor-led wealth platform, analytics tools and alternative investment capabilities. With about USD 221 billion of assets under management and USD 1.6 trillion of assets under advisement as of June 30, 2026, it adds meaningful scale. The Business will join Marsh's people and investments division. For Marsh (NYSE:MRSH), the strategic logic is to deepen relationships with institutional and retirement clients that already use its consulting services, and to capture fee-based revenue that is less sensitive to insurance pricing cycles. Wilshire was acquired by its Private Equity owners in 2021, and the sale marks their exit. The price was not disclosed, so investors cannot yet judge the valuation or Earnings impact.
MaxCyte Doubles Its Revenue Base
MaxCyte supplies electroporation systems used to engineer cells for therapies. Akron Bio makes reagents, media and other materials used in cell and gene therapy manufacturing, and is expected to generate about USD 28 million of revenue and USD 7 million to USD 8 million of EBITDA in 2026. The USD 151.8 million price includes USD 105.0 million in cash at closing, 20,639,733 MaxCyte shares valued at about USD 26.8 million and USD 20.0 million in guaranteed deferred payments, split equally between January 2028 and January 2029. MaxCyte is financing part of the cash with a new Credit Facility of up to USD 75.0 million. The company says the combination should nearly double its revenue base and reduce combined annual cash burn to below USD 10 million in 2027. MaxCyte's shares dipped on the announcement, reflecting the use of cash, new Debt and share issuance.
What to Watch
Both deals reflect a broader theme of companies buying recurring, fee-based or consumable revenue streams. For Marsh (NYSE:MRSH), investors should watch for disclosure of the purchase price and expected accretion, regulatory approvals and client retention through closing, since advisory relationships can be sensitive to ownership changes. Rising interest rates and market Volatility can also affect asset-based fees. For MaxCyte, integration risk, debt servicing and the pace of cell therapy Manufacturing Demand will determine whether the Acquisition delivers the promised path to profitability. Arcline's decision to take part of its payment in MaxCyte stock signals confidence in the combined company, but dilution for existing holders is a consideration. Closing timelines, before year-end for MaxCyte and in the first quarter of 2027 for Marsh, are the next milestones.
Where Things Stand
Marsh (NYSE:MRSH) agreed to buy Wilshire, with about USD 221 billion of assets under management, to expand its investments business, with terms undisclosed and closing expected in early 2027. MaxCyte agreed to buy Akron Bio for USD 151.8 million to nearly double its revenue base. Disclosure of Marsh's price, client retention and MaxCyte's integration and cash burn are the next checkpoints.


_11_19_2026_12_58_12_592184.jpg)



Please wait processing your request...